Detail akcie Viropro online

Business Summary: Viropro, Inc. is engaged in the development and manufacturing of biopharmaceutical drugs. The Company conducts operations primarily through its subsidiary, Alpha Biologics Sdn Bhd (Alpha) located in Penang, Malaysia. The Company intends to offer solution to the biopharma industry from drug concept through to product manufacturing. The Alpha facility consists of approximately 50,000 square feet of research and production space. The Alpha facility is designed to support the scale-up and manufacture of monoclonal antibodies.
Financial Summary: BRIEF: For the nine months ended 30 September 2011, Viropro, Inc. revenues increased from $397K to $839K. Net loss increased from $874K to $2.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Consulting fees increase from $220K to $813K (expense), Interest expense increase from $13K to $237K (expense).